News

BenevolentAI announces first patient dosed in its Atopic Dermatitis clinical trial

BenevolentAI, a leader in the application of AI and machine learning in drug discovery and development, announced dosing of the first patient in its randomised first-in-human clinical trial of BEN-2293, a molecule designed and developed by BenevolentAI to treat Atopic Dermatitis.

London, 11 February 2020 - This significant milestone sees a best in class, novel multi-target drug developed using BenevolentAI's scientific and technical expertise now entering human clinical trials.

BEN-2293 is a potent and selective small-molecule Pan-Trk antagonist formulated for topical delivery, with a pharmacokinetic profile designed for low systemic exposure to deliver the optimal safety and efficacy profile in the treatment of itch and inflammation associated with Atopic Dermatitis. In this initial trial, BEN-2293 will be studied in adult patients with mild to moderate disease.

Atopic Dermatitis is characterised as a chronic relapsing inflammatory skin condition which manifests as itchy, inflamed skin. The addressable global patient population is estimated at 230 million. Mild to moderate Atopic Dermatitis affects approximately 70% of all patients, with prevalence rising worldwide.

The current standard of care for the topical treatment of Atopic Dermatitis includes corticosteroids and calcineurin inhibitors which have limitations of use and adverse side effects. There remains a high unmet need for patients that are either non-responders or refractory to currently available treatments. BEN-2293 is positioned to address both the inflammation and itch associated with Atopic Dermatitis in both adults and children, representing a comprehensive, new treatment available for a broad patient population.

Anne Phelan, Chief Scientific Officer at BenevolentAI, commented,
“The poor treatment options available for Atopic Dermatitis patients make the disease difficult to endure. It can impact the quality of life and psychosocial wellbeing, particularly among children, who make up around 10-20% of patients. New ways to treat this disease are desperately needed, and we believe our molecule has strong potential to address this serious unmet need without the use of topical steroids. The BEN-2293 trial also marks an important first step in the development of our in-house drug pipeline, and we are excited to be progressing this candidate into the clinic.”



Media enquiries

Rajin Kang

rajin.kang@benevolent.ai 

About BenevolentAI (www.benevolent.com)

BenevolentAI creates and applies AI and machine learning to transform the way medicines are discovered and developed. Benevolent integrates its technology into every step of the drug discovery process, from hypothesis generation to early-stage clinical development. BenevolentAI is headquartered in London with a research facility in Cambridge (UK) and offices in New York. BenevolentAI has active R&D drug programmes in disease areas such as ALS, Ulcerative Colitis, Atopic Dermatitis and Oncology and has research and commercial collaborations with AstraZeneca and Novartis.


More Posts

You Might Also Like

Blog
Tech Nation Visa: the gateway to world-leading UK tech jobs
Drawing attention to the Tech Nation Visa, a great initiative that enables the brightest international talent to live and work in the UK.
Feb 19, 2021
News
BenevolentAI and AstraZeneca achieve collaboration milestone with novel AI-generated chronic kidney disease target
BenevolentAI and AstraZeneca hit collaboration milestone with an AI-generated CKD target from the partnership entering AstraZeneca’s portfolio.
Jan 27, 2021
News
ACTT-2 trial results published in the New England Journal of Medicine validate baricitinib’s efficacy in combination with remdesivir in hospitalised COVID-19 patients
Peer-reviewed data from the ACTT-2 further validate BenevolentAI’s hypothesis for baricitinib as a potential COVID-19 treatment.
Jan 15, 2021
Blog
Joanna Shields speaks at the Global Partnership on Artificial Intelligence
BenevolentAI CEO Joanna Shields opened the final plenary of the Global Partnership on Artificial Intelligence (GPAI) summit with a powerful message on the future of AI.
Dec 11, 2020
Blog
BenevolentAI wins Innovation Award at 2020 Scrip Awards
BenevolentAI wins the Innovation Award at the prestigious 2020 Scrip Awards for our work in artificial intelligence applied drug discovery.
Dec 11, 2020
Blog
Intern at BenevolentAI part II: what to expect from your internship
What makes the best tech internships? Learn about what our 2020 interns have been up to, and how interning at Benevolent helped their career development.
Dec 2, 2020